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ABSTRACT 
 
     Breast cancer (BC) accounts for one of the major health problems around the world. Since the 
diagnosis process can have great effect on therapy outcomes, we studied the biomarkers specific to 
breast tumors stage I based on examining different Iranian patients. Cases from different stages were 
examined to discover their highly expressed proteins. In addition, pathologic evaluations were performed 
as the diagnosis procedure. Considering positive percentage of over-expressed protein in different stages 
in the population, it is guessed that over-expression of ErBb2 and PR are positively correlated, while P53 
is in negative correlation with them. Therefore, these molecules can probably account for stage I 
biological marker. This study suggests that alterations in over-expression of specific biomarkers in 
different stages may be associated to the stage classification, and can help achieve more effective 
therapies of this malignancy. 
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INTRODUCTION 
     Breast cancer as the most frequent 
malignancy in women in the East is a primary 
cause of death in women, with 1.15 million new 
cases and 410,000 deaths in 2002 [1], which is 
about 18% of women cancers [2]. Furthermore, 
it is the most common cancer among Iranian 
women with a considerable proportion in stage 
II or III at diagnosis [3]. Breast cancer occurs 
with an unregulated developing of abnormal 
cells in different parts of breast tissue which 
probably grows in milk ducts and glands of its 
tissue. The two main kinds of breast cancer are: 
ductal carcinoma and lobular carcinoma [4, 5]. 
In this malignant disease, about one-third of 
those with primary breast cancer have 
reappearance of micro metastasis after about 10 
years. Consequently, it is essential to discover a 
reliable biomarker for examining this disease 
[6]. Despite new advances in the resolution of 
imaging techniques such as commonplace 
mammography, they still lack adequate 
sensitivity and specificity [6-8]. On the other 
hand, diagnosis based on molecular approaches 
has been shown promising in this field of study 
[9, 10]. Marker panels have the potential to 
detect cancer biomarker evaluations [11]. In 
fact, biological markers have been 
incrementally used for improving population 
screening,  diagnosis, prognosis, therapeutic 
decisions, and staging [12], which have 
considerably decreased the mortality rates [4]. 
There are lots of established biomarkers as an 
indicator for breast cancer such as Human 
Epidermal Growth Factor Receptor 2 (HER2) 
(ErBbr2), which has been reported positive in 
breast cancer previously [13, 14], and estrogen 
receptor (ER), which is certainly the most 
prominent biomarker in breast cancer, in that it 
provides the index for sensitivity to endocrine 
treatment [15]. In  addition, P53 is another 
comparatively reliable source for cancer 
analysis [16], and also PR as highly expressed 
protein in low stage tumors. Staging is one of 
the essential prognostic factors for patients with 
BC [17]. Indeed, amplification or over-
expression of these genes have been revealed to 
play a key role in the pathogenesis and 
progression of definite aggressive forms 
of breast cancer and it has developed to become 
a significant biomarker and target of therapy for 
the disorder recently [18]. It is divided into loco 
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regional and distant or systemic based on the 
level of disease progress [19]. This research 
underlies the breast cancer staging diagnostic 
based on clinical markers examinations. 
 
MATERIALS AND METHODS 
   A total number of 191 Iranian women patients 
were visited in Shohada Hospital between the 
years 1991 and 2001 that in average most of 
them were followed up for five years and 
validated for breast cancer tumors with different 
grades based on their pathological diagnosis. A 
standard medical history of all cases was 
obtained examining stages, recording of race, 
and dates of birth, diagnosis of breast cancer 
and last menstrual period, the date and type of 
therapy comprising: radiotherapy, 
chemotherapy, hormone therapy and surgery of 
the tumor, the time of first recurrence, and 
dates, agents and the recorded result of previous 
treatment of recurrent breast cancer. Based on 
these records, the average age among patients 
when were diagnosed with these stages was 45 
years.  Five stages of breast cancer in these 
patients were evaluated in this study; from low 
grade to invasive breast cancer, of which 21 
were in stage 0, and 29, 61, 30, and 50 of them 
were in stage I, II, III and IV, respectively. 
Among them the percentage of highly amplified 
proteins were investigated by plotting methods. 
 
RESULTS 
   Number of patients with three over-expressed 
markers in different grades is given in Table 1. 
  
Table 1.  Collection of population-based cancer staging 
with their markers presence 
 Markers 
 
 
 
Stages 
ErBb2 P53 PR Total 
number 
of cases 
0 8 16 8 21 
I 19 11 23 29 
II 31 32 40 61 
III 18 20 19 30 
IV 38 32 30 50 
 
 
In order to determine biomarker specific to 
stage I, three over-expressed proteins among a 
series of 191 patients with discrete grades of 
breast tumor were evaluated. (See figures 1, 2, 
and 3) 
 
 
Figure 1. Erbb2+ displayed different positive percentages 
in the population of study with different stages of BC.   
 
 
Figure 2. It shows the rate of P53 positive percentage in 
population of different stages from low grade to severe 
types.  
 
  
 
Figure 3.  It shows the rate of PR positive percentage in 
population of grades from 0 to 4. 
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DISCUSSION 
     Protein biomarkers have lately been 
seriously researched in their key roles in the 
recognition, quantification, and follow up of 
different kinds of breast cancer [20]. In other 
words, owing to these evaluations such as the 
ability to prospectively identify stages, this 
malignancy has underwent several changes 
recently which enable the application of more 
individualized treatment optimizing to different 
molecular subgroups, as under treatment or 
incorrect therapy has to be avoided [15]. 
Inasmuch as detection in late stages may not 
lead to appropriate therapy, cancer detection in 
low grades such as stage 0 and I is vital for 
acceptable treatment outcomes [21]. Some 
breast cancer biological indicators have been 
evaluated in this study, which there was a 
significant correlation between three of them. 
From table 1 it can be inferred that 8 out of 21 
cases in stage 0, 19 out of 29 in stage I, 31 out 
of 61 in stage II, 18 out of 30 in stage III, and 
38 out of 50 in stage IV were reported with 
ErBb2 positive over-expression; 16 out of 21 
patients in stage 0, 11 out of 29 in stage I, 32 
out of 61 in stage II, 20 out of 30 in stage III, 
and 32 out of 50 in stage IV were reported with 
high expression in P53. In addition, 8 out of 21 
of them in stage 0, 23 out of 29 in stage I, 40 
out of 61 in stage II, 19 out of 30 in stage III, 
and 30 out of 50 in stage IV were diagnosed 
with PR positive amplifications.  
As it is depicted in Figure 1, Erbb2 has different 
expressions in different stages of these patients. 
Now that its percentage is significantly great 
among different grades, it can possibly account 
for the biomarker of stage two. Here observed 
in Figure 2, the percentage of protein expression 
level of P53 is noticeably high in different 
stages, while in stage two it significantly 
decreases in the population. Furthermore, in 
Figure 3, the percentage of PR is examined, and 
the degree of this biological marker has raised 
in the population of stage I, which is in positive 
correlation with Erbb2 and negative correlation 
with P53. In other words, ErBb2, P53, and PR 
can account for potential biomarkers profile in 
stage I examination. Statistical analysis 
(Binomial Test) was investigated in this study 
for more resolution. The finding indicated that 
ErBb2 can differentiate stage 0 versus Stage I (P 
value is about 0.05) and also stage I compared 
to the higher stages (P value less than 0.001). 
P53 cannot differentiate the stages 0 and I but it 
differentiates I from the higher stages (P value 
less than 0.001). PR, like ErBb2, differentiates 
stage I from stage 0 and the other higher stages 
with P value less than 0.01 and 0.001, 
respectively. However, ER is a significant 
biomarker for breast cancer diagnostic aspects; 
here it could not differentiated stage 0 from the 
other stages.  Finally based on these findings, 
ErBb2, P53 and PR can be considered as 
suitable criteria for diagnostic probes for stage I 
of breath cancer. 
 
CONCLUSION 
     In brief, these markers with significant 
changes probably have high sensitivity and 
specificity. Hence, they can be possibly useful 
in characteristic stage I of breast cancer, and 
finally may lessen the therapeutic failures of 
breast cancer patients. 
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